AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine

Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine

Novartis reports data from trial of IgA nephropathy treatment

IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

Merck India appoints Dhananjay Singh as MD Merck Life Science in India

CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData

The period from 2020 to 2022 witnessed a remarkable surge in deal worth

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program

Ginkgo Bioworks and Novo Nordisk to collaborate across R&D value chain

The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio

Evonik launches Botanicals & Natural Actives business segment

Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market